Genetic variation in the human genome controls a compendium of cellular and physiological components that make up human biology. The Ray Lab is interested in better understanding how genetic variation tunes our immune system and how this can put individuals at risk for autoimmune diseases, which is a vital step in developing more effective therapeutics with fewer side effects.
Because most genetic risk for autoimmune diseases occurs in non-coding regions of the genome, the Ray lab studies how non-coding genetic variants modulate cis-regulatory regions and alter immune cell activities that lead to autoimmune disease susceptibility. We prioritize likely disease-causal variants and cis-regulatory regions, and, in human and mouse systems, identify variant target genes and pathways and define their functional effects on immune cells.
These studies will inform efforts for personalized therapies and disease prevention.
John Ray, PhD
Open Position: Research Technician I
Ingrid Harten, PhD
Alex Ho, PhD
Defining variants that act collectively to promote disease
Mapping cis-regulatory regions that control immune cell function genome-wide
Prioritizing autoimmune disease-causal variants in immune cells
John Ray, PhD, Receives NIH New Innovator Award
Lupus Nephritis: New Approach Could Pave the Way for Innovative Treatments
When Jessica Hamerman, PhD, was perusing research papers in 2021, one discovery stopped her in her tracks — and ultimately put her on a whole new research path.
A Heartfelt Thank You: One Scientist Shares How Donors Make an Impact at BRI
This giving season, on behalf of our team, I extend a heartfelt thank you to all BRI donors and share some of the meaningful ways your philanthropy supports our work.